
### [MONDO:0017594](http://purl.obolibrary.org/obo/MONDO_0017594)
**Label:** indolent B-cell non-Hodgkin lymphoma

**Subclasses:** [MONDO:0007190](http://purl.obolibrary.org/obo/MONDO_0007190) (leukemia, chronic lymphocytic, susceptibility to, 2), [MONDO:0017599](http://purl.obolibrary.org/obo/MONDO_0017599) (splenic diffuse red pulp small b-cell lymphoma), [MONDO:0001607](http://purl.obolibrary.org/obo/MONDO_0001607) (intrapelvic lymph node leukemic reticuloendotheliosis), [MONDO:0018621](http://purl.obolibrary.org/obo/MONDO_0018621) (lymphoplasmacytic lymphoma without IgM production), [MONDO:0007926](http://purl.obolibrary.org/obo/MONDO_0007926) (Waldenstrom macroglobulinemia), [MONDO:0003864](http://purl.obolibrary.org/obo/MONDO_0003864) (CLL/SLL), [MONDO:0006119](http://purl.obolibrary.org/obo/MONDO_0006119) (breast mucosa-associated lymphoid tissue lymphoma), [MONDO:0004478](http://purl.obolibrary.org/obo/MONDO_0004478) (pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma), [MONDO:0015819](http://purl.obolibrary.org/obo/MONDO_0015819) (indolent primary cutaneous b-cell lymphoma), [MONDO:0004110](http://purl.obolibrary.org/obo/MONDO_0004110) (refractory hairy cell leukemia), [MONDO:0004152](http://purl.obolibrary.org/obo/MONDO_0004152) (postgerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma), [MONDO:0015814](http://purl.obolibrary.org/obo/MONDO_0015814) (primary cutaneous follicle center lymphoma), [MONDO:0018906](http://purl.obolibrary.org/obo/MONDO_0018906) (follicular lymphoma), [MONDO:0015813](http://purl.obolibrary.org/obo/MONDO_0015813) (primary cutaneous marginal zone b-cell lymphoma), [MONDO:0017600](http://purl.obolibrary.org/obo/MONDO_0017600) (hairy cell leukemia variant), [MONDO:0019469](http://purl.obolibrary.org/obo/MONDO_0019469) (T-cell large granular lymphocyte leukemia), [MONDO:0012491](http://purl.obolibrary.org/obo/MONDO_0012491) (WM2), [MONDO:0019465](http://purl.obolibrary.org/obo/MONDO_0019465) (Nodal marginal zone b-cell lymphoma), [MONDO:0013088](http://purl.obolibrary.org/obo/MONDO_0013088) (FL1), [MONDO:0004948](http://purl.obolibrary.org/obo/MONDO_0004948) (B-cell chronic lymphocytic leukemia), [MONDO:0019462](http://purl.obolibrary.org/obo/MONDO_0019462) (splenic marginal zone lymphoma), [MONDO:0004104](http://purl.obolibrary.org/obo/MONDO_0004104) (splenic manifestation of hairy cell leukemia), [MONDO:0006226](http://purl.obolibrary.org/obo/MONDO_0006226) (gastric mucosa-associated lymphoid tissue lymphoma), [MONDO:0012936](http://purl.obolibrary.org/obo/MONDO_0012936) (leukemia, chronic lymphocytic, susceptibility to, 5), [MONDO:0007897](http://purl.obolibrary.org/obo/MONDO_0007897) (leukemia, chronic lymphocytic), [MONDO:0006420](http://purl.obolibrary.org/obo/MONDO_0006420) (small intestinal mucosa-associated lymphoid tissue lymphoma), [MONDO:0006464](http://purl.obolibrary.org/obo/MONDO_0006464) (thyroid gland mucosa-associated lymphoid tissue lymphoma), [MONDO:0007650](http://purl.obolibrary.org/obo/MONDO_0007650) (MALT lymphoma), [MONDO:0002083](http://purl.obolibrary.org/obo/MONDO_0002083) (Richter's syndrome), [MONDO:0012935](http://purl.obolibrary.org/obo/MONDO_0012935) (leukemia, chronic lymphocytic, susceptibility to, 4), [MONDO:0017604](http://purl.obolibrary.org/obo/MONDO_0017604) (marginal zone lymphoma), [MONDO:0012934](http://purl.obolibrary.org/obo/MONDO_0012934) (leukemia, chronic lymphocytic, susceptibility to, 3), [MONDO:0012318](http://purl.obolibrary.org/obo/MONDO_0012318) (leukemia, chronic lymphocytic, susceptibility to, 1), [MONDO:0018935](http://purl.obolibrary.org/obo/MONDO_0018935) (hairy cell leukemia), 

**Mapped go classes:** [GO:0008063](http://purl.obolibrary.org/obo/GO_0008063) (Toll signaling pathway), [GO:0014069](http://purl.obolibrary.org/obo/GO_0014069) (postsynaptic density), [GO:0032494](http://purl.obolibrary.org/obo/GO_0032494) (response to peptidoglycan), [GO:0007254](http://purl.obolibrary.org/obo/GO_0007254) (JNK cascade), [GO:0007178](http://purl.obolibrary.org/obo/GO_0007178) (transmembrane receptor protein serine/threonine kinase signaling pathway), [GO:0051092](http://purl.obolibrary.org/obo/GO_0051092) (positive regulation of NF-kappaB transcription factor activity), [GO:1900017](http://purl.obolibrary.org/obo/GO_1900017) (positive regulation of cytokine production involved in inflammatory response), [GO:0043621](http://purl.obolibrary.org/obo/GO_0043621) (protein self-association), [GO:0006954](http://purl.obolibrary.org/obo/GO_0006954) (inflammatory response), [GO:0002237](http://purl.obolibrary.org/obo/GO_0002237) (response to molecule of bacterial origin), [GO:0032449](http://purl.obolibrary.org/obo/GO_0032449) (CBM complex), [GO:0002755](http://purl.obolibrary.org/obo/GO_0002755) (MyD88-dependent toll-like receptor signaling pathway), [GO:0006955](http://purl.obolibrary.org/obo/GO_0006955) (immune response), [GO:0002238](http://purl.obolibrary.org/obo/GO_0002238) (response to molecule of fungal origin), [GO:0050671](http://purl.obolibrary.org/obo/GO_0050671) (positive regulation of lymphocyte proliferation), [GO:0006915](http://purl.obolibrary.org/obo/GO_0006915) (apoptotic process), [GO:0005829](http://purl.obolibrary.org/obo/GO_0005829) (cytosol), [GO:0032760](http://purl.obolibrary.org/obo/GO_0032760) (positive regulation of tumor necrosis factor production), [GO:0050830](http://purl.obolibrary.org/obo/GO_0050830) (defense response to Gram-positive bacterium), [GO:0009682](http://purl.obolibrary.org/obo/GO_0009682) (induced systemic resistance), [GO:0032481](http://purl.obolibrary.org/obo/GO_0032481) (positive regulation of type I interferon production), [GO:0032680](http://purl.obolibrary.org/obo/GO_0032680) (regulation of tumor necrosis factor production), [GO:0005121](http://purl.obolibrary.org/obo/GO_0005121) (Toll binding), [GO:0042981](http://purl.obolibrary.org/obo/GO_0042981) (regulation of apoptotic process), [GO:0042101](http://purl.obolibrary.org/obo/GO_0042101) (T cell receptor complex), [GO:0043234](http://purl.obolibrary.org/obo/GO_0043234) (protein complex), [GO:0042742](http://purl.obolibrary.org/obo/GO_0042742) (defense response to bacterium), [GO:0005886](http://purl.obolibrary.org/obo/GO_0005886) (plasma membrane), [GO:0002376](http://purl.obolibrary.org/obo/GO_0002376) (immune system process), [GO:0005634](http://purl.obolibrary.org/obo/GO_0005634) (nucleus), [GO:0005515](http://purl.obolibrary.org/obo/GO_0005515) (protein binding), [GO:0044130](http://purl.obolibrary.org/obo/GO_0044130) (negative regulation of growth of symbiont in host), [GO:0010628](http://purl.obolibrary.org/obo/GO_0010628) (positive regulation of gene expression), [GO:0070555](http://purl.obolibrary.org/obo/GO_0070555) (response to interleukin-1), [GO:0010468](http://purl.obolibrary.org/obo/GO_0010468) (regulation of gene expression), [GO:0031663](http://purl.obolibrary.org/obo/GO_0031663) (lipopolysaccharide-mediated signaling pathway), [GO:0032675](http://purl.obolibrary.org/obo/GO_0032675) (regulation of interleukin-6 production), [GO:0050727](http://purl.obolibrary.org/obo/GO_0050727) (regulation of inflammatory response), [GO:0032755](http://purl.obolibrary.org/obo/GO_0032755) (positive regulation of interleukin-6 production), [GO:0090557](http://purl.obolibrary.org/obo/GO_0090557) (establishment of endothelial intestinal barrier), [GO:0043123](http://purl.obolibrary.org/obo/GO_0043123) (positive regulation of I-kappaB kinase/NF-kappaB signaling), [GO:0009615](http://purl.obolibrary.org/obo/GO_0009615) (response to virus), [GO:0048661](http://purl.obolibrary.org/obo/GO_0048661) (positive regulation of smooth muscle cell proliferation), [GO:2000338](http://purl.obolibrary.org/obo/GO_2000338) (regulation of chemokine (C-X-C motif) ligand 1 production), [GO:0032747](http://purl.obolibrary.org/obo/GO_0032747) (positive regulation of interleukin-23 production), [GO:0002218](http://purl.obolibrary.org/obo/GO_0002218) (activation of innate immune response), [GO:0045351](http://purl.obolibrary.org/obo/GO_0045351) (type I interferon biosynthetic process), [GO:0019221](http://purl.obolibrary.org/obo/GO_0019221) (cytokine-mediated signaling pathway), [GO:0032740](http://purl.obolibrary.org/obo/GO_0032740) (positive regulation of interleukin-17 production), [GO:0042802](http://purl.obolibrary.org/obo/GO_0042802) (identical protein binding), [GO:0070935](http://purl.obolibrary.org/obo/GO_0070935) (3'-UTR-mediated mRNA stabilization), [GO:0140052](http://purl.obolibrary.org/obo/GO_0140052) (cellular response to oxidised low-density lipoprotein particle stimulus), [GO:0007165](http://purl.obolibrary.org/obo/GO_0007165) (signal transduction), [GO:1902622](http://purl.obolibrary.org/obo/GO_1902622) (regulation of neutrophil migration), [GO:1901532](http://purl.obolibrary.org/obo/GO_1901532) (regulation of hematopoietic progenitor cell differentiation), [GO:1901534](http://purl.obolibrary.org/obo/GO_1901534) (positive regulation of hematopoietic progenitor cell differentiation), [GO:0007166](http://purl.obolibrary.org/obo/GO_0007166) (cell surface receptor signaling pathway), [GO:0005102](http://purl.obolibrary.org/obo/GO_0005102) (receptor binding), [GO:0005149](http://purl.obolibrary.org/obo/GO_0005149) (interleukin-1 receptor binding), [GO:0042127](http://purl.obolibrary.org/obo/GO_0042127) (regulation of cell proliferation), [GO:0060337](http://purl.obolibrary.org/obo/GO_0060337) (type I interferon signaling pathway), [GO:0005737](http://purl.obolibrary.org/obo/GO_0005737) (cytoplasm), [GO:0046696](http://purl.obolibrary.org/obo/GO_0046696) (lipopolysaccharide receptor complex), [GO:0045087](http://purl.obolibrary.org/obo/GO_0045087) (innate immune response), [GO:0046330](http://purl.obolibrary.org/obo/GO_0046330) (positive regulation of JNK cascade), [GO:0016064](http://purl.obolibrary.org/obo/GO_0016064) (immunoglobulin mediated immune response), [GO:0030593](http://purl.obolibrary.org/obo/GO_0030593) (neutrophil chemotaxis), [GO:0032496](http://purl.obolibrary.org/obo/GO_0032496) (response to lipopolysaccharide), [GO:2000341](http://purl.obolibrary.org/obo/GO_2000341) (regulation of chemokine (C-X-C motif) ligand 2 production), [GO:0035325](http://purl.obolibrary.org/obo/GO_0035325) (Toll-like receptor binding), [GO:0070976](http://purl.obolibrary.org/obo/GO_0070976) (TIR domain binding), [GO:0045080](http://purl.obolibrary.org/obo/GO_0045080) (positive regulation of chemokine biosynthetic process), 

**Class expressions from DL-Learner:**

- Thing 52.93%
- [GO:0050830](http://purl.obolibrary.org/obo/GO_0050830) (defense response to Gram-positive bacterium) 52.38%
- [GO:0009682](http://purl.obolibrary.org/obo/GO_0009682) (induced systemic resistance) 52.38%
- [GO:0042742](http://purl.obolibrary.org/obo/GO_0042742) (defense response to bacterium) and [GO:0045087](http://purl.obolibrary.org/obo/GO_0045087) (innate immune response) 52.38%
- [GO:0009617](http://purl.obolibrary.org/obo/GO_0009617) (response to bacterium) and [GO:0045087](http://purl.obolibrary.org/obo/GO_0045087) (innate immune response) 52.38%
- [GO:0006955](http://purl.obolibrary.org/obo/GO_0006955) (immune response) and [GO:0042742](http://purl.obolibrary.org/obo/GO_0042742) (defense response to bacterium) 52.38%
- [GO:0006955](http://purl.obolibrary.org/obo/GO_0006955) (immune response) and [GO:0009617](http://purl.obolibrary.org/obo/GO_0009617) (response to bacterium) 52.38%
- [GO:0002376](http://purl.obolibrary.org/obo/GO_0002376) (immune system process) and [GO:0042742](http://purl.obolibrary.org/obo/GO_0042742) (defense response to bacterium) 52.38%
- [GO:0002376](http://purl.obolibrary.org/obo/GO_0002376) (immune system process) and [GO:0009617](http://purl.obolibrary.org/obo/GO_0009617) (response to bacterium) 52.38%
- [GO:0042742](http://purl.obolibrary.org/obo/GO_0042742) (defense response to bacterium) 45.59%
- [GO:0009617](http://purl.obolibrary.org/obo/GO_0009617) (response to bacterium) 45.59%
- [GO:0009617](http://purl.obolibrary.org/obo/GO_0009617) (response to bacterium) and [GO:0098542](http://purl.obolibrary.org/obo/GO_0098542) (defense response to other organism) 45.59%
- [GO:0006952](http://purl.obolibrary.org/obo/GO_0006952) (defense response) and [GO:0009617](http://purl.obolibrary.org/obo/GO_0009617) (response to bacterium) 45.59%
- [GO:0006950](http://purl.obolibrary.org/obo/GO_0006950) (response to stress) and [GO:0009617](http://purl.obolibrary.org/obo/GO_0009617) (response to bacterium) 45.59%
- [GO:0042742](http://purl.obolibrary.org/obo/GO_0042742) (defense response to bacterium) and ([GO:0005734](http://purl.obolibrary.org/obo/GO_0005734) (obsolete box C + D snoRNP protein) or [GO:0008150](http://purl.obolibrary.org/obo/GO_0008150) (biological_process)) 45.59%


